SG11201500585XA - 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel - Google Patents
3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channelInfo
- Publication number
- SG11201500585XA SG11201500585XA SG11201500585XA SG11201500585XA SG11201500585XA SG 11201500585X A SG11201500585X A SG 11201500585XA SG 11201500585X A SG11201500585X A SG 11201500585XA SG 11201500585X A SG11201500585X A SG 11201500585XA SG 11201500585X A SG11201500585X A SG 11201500585XA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- potassium channel
- activated potassium
- calcium activated
- oxazolidinone derivatives
- Prior art date
Links
- -1 3,4-disubstituted oxazolidinone Chemical class 0.000 title 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 title 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190319 | 2012-10-29 | ||
| PCT/EP2013/072361 WO2014067861A1 (en) | 2012-10-29 | 2013-10-25 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201500585XA true SG11201500585XA (en) | 2015-04-29 |
Family
ID=47143594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500585XA SG11201500585XA (en) | 2012-10-29 | 2013-10-25 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
Country Status (23)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
| MA55357A (fr) | 2019-03-22 | 2022-01-26 | Saniona As | Nouveaux inhibiteurs des canaux potassiques |
| MX2023003306A (es) * | 2020-09-22 | 2023-06-06 | Saniona As | Inhibidores del canal de potasio novedosos. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2538424C2 (de) * | 1975-08-29 | 1983-01-05 | Nordmark-Werke Gmbh, 2000 Hamburg | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat |
| KR940006634B1 (ko) * | 1985-09-09 | 1994-07-23 | 오쓰까 세이야꾸 가부시끼가이샤 | 2-옥사-이소세펨 화합물의 제조방법 |
| KR930703262A (ko) * | 1990-11-06 | 1993-11-29 | 스튜어트 알. 슈터 | 이미다졸리디논 화합물 |
| DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| WO1997031892A1 (fr) * | 1996-03-01 | 1997-09-04 | Sankyo Company, Limited | Derives d'acide hydroxamique |
| JP2002531552A (ja) * | 1998-12-04 | 2002-09-24 | ニューロサーチ、アクティーゼルスカブ | イオンチャネル調節剤としての新規ベンズイミダゾロン−、ベンズオキサゾロン−又はベンゾチアゾロン−誘導体 |
| HK1049004A1 (en) * | 2000-01-20 | 2003-04-25 | Eisai Co., Ltd. | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same |
| JP3966693B2 (ja) * | 2000-01-20 | 2007-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素環化合物およびそれらを含んでなる医薬組成物 |
| JP4295505B2 (ja) * | 2000-11-22 | 2009-07-15 | バイエル アクチェンゲゼルシャフト | 新規なラクタム置換ピラゾロピリジン誘導体 |
| AU2005267884B2 (en) | 2004-07-29 | 2011-04-21 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| US7378530B2 (en) * | 2005-02-22 | 2008-05-27 | Nereus Pharmaceuticals, Inc. | Anti-cancer and anti-microbial 5-membered heterocyclic compounds |
| US20100056637A1 (en) | 2005-12-20 | 2010-03-04 | Icagen, Inc. | Treatment methods using triaryl methane compounds |
| WO2007109098A2 (en) * | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
| TW201026708A (en) | 2008-12-12 | 2010-07-16 | Solvay Pharm Bv | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers |
| WO2010123997A1 (en) * | 2009-04-22 | 2010-10-28 | Achaogen, Inc. | Carbacephem beta-lactam antibiotics |
-
2013
- 2013-10-25 KR KR1020157011024A patent/KR20150075091A/ko not_active Withdrawn
- 2013-10-25 BR BR112015003996A patent/BR112015003996A2/pt not_active IP Right Cessation
- 2013-10-25 UA UAA201504977A patent/UA114649C2/uk unknown
- 2013-10-25 CA CA2879249A patent/CA2879249A1/en not_active Abandoned
- 2013-10-25 MA MA38135A patent/MA38135B1/fr unknown
- 2013-10-25 IN IN961DEN2015 patent/IN2015DN00961A/en unknown
- 2013-10-25 EA EA201590729A patent/EA026161B1/ru not_active IP Right Cessation
- 2013-10-25 WO PCT/EP2013/072361 patent/WO2014067861A1/en active Application Filing
- 2013-10-25 JP JP2015538458A patent/JP6216385B2/ja not_active Expired - Fee Related
- 2013-10-25 SG SG11201500585XA patent/SG11201500585XA/en unknown
- 2013-10-25 AU AU2013339607A patent/AU2013339607A1/en not_active Abandoned
- 2013-10-25 MX MX2015002399A patent/MX2015002399A/es unknown
- 2013-10-25 PE PE2015000296A patent/PE20150775A1/es not_active Application Discontinuation
- 2013-10-25 EP EP13783333.1A patent/EP2912034B1/en not_active Not-in-force
- 2013-10-25 CN CN201380056503.4A patent/CN104781256B/zh not_active Expired - Fee Related
- 2013-10-28 AR ARP130103922A patent/AR093168A1/es unknown
- 2013-10-28 TW TW102138950A patent/TW201422596A/zh unknown
-
2015
- 2015-01-16 CO CO15008510A patent/CO7170170A2/es unknown
- 2015-02-10 PH PH12015500292A patent/PH12015500292A1/en unknown
- 2015-02-19 IL IL237331A patent/IL237331A0/en unknown
- 2015-03-20 CR CR20150159A patent/CR20150159A/es unknown
- 2015-04-10 CL CL2015000906A patent/CL2015000906A1/es unknown
- 2015-04-29 US US14/699,144 patent/US9611232B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA026161B1 (ru) | 2017-03-31 |
| US20150246894A1 (en) | 2015-09-03 |
| CN104781256B (zh) | 2017-09-29 |
| JP6216385B2 (ja) | 2017-10-18 |
| EP2912034B1 (en) | 2017-05-31 |
| CL2015000906A1 (es) | 2015-09-11 |
| MA38135B1 (fr) | 2018-11-30 |
| AR093168A1 (es) | 2015-05-20 |
| MA38135A2 (fr) | 2016-11-30 |
| WO2014067861A1 (en) | 2014-05-08 |
| IL237331A0 (en) | 2015-04-30 |
| PH12015500292A1 (en) | 2015-04-20 |
| EA201590729A1 (ru) | 2015-07-30 |
| CO7170170A2 (es) | 2015-01-28 |
| IN2015DN00961A (enrdf_load_stackoverflow) | 2015-06-12 |
| EP2912034A1 (en) | 2015-09-02 |
| MX2015002399A (es) | 2015-06-10 |
| CA2879249A1 (en) | 2014-05-08 |
| CR20150159A (es) | 2015-04-30 |
| TW201422596A (zh) | 2014-06-16 |
| UA114649C2 (uk) | 2017-07-10 |
| CN104781256A (zh) | 2015-07-15 |
| JP2015535231A (ja) | 2015-12-10 |
| KR20150075091A (ko) | 2015-07-02 |
| PE20150775A1 (es) | 2015-05-21 |
| BR112015003996A2 (pt) | 2017-07-04 |
| US9611232B2 (en) | 2017-04-04 |
| AU2013339607A1 (en) | 2015-02-05 |
| HK1207632A1 (en) | 2016-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238876A0 (en) | Indoleamine 2,3-dioxygenase inhibitors, preparations containing them and their uses | |
| IL245184A0 (en) | Prostacyclin compounds, preparations and methods of using them | |
| AP2014007835A0 (en) | Oxazolidin-2-one compounds and uses thereof as P13KS inhibitors | |
| IL240196B (en) | Amide compounds, preparations containing them and their uses | |
| IL246252A0 (en) | Diaminopyrimidyl derivative compounds, their compositions and methods of treatment | |
| IL238958A0 (en) | Glutamase inhibitors, preparations containing them and their uses | |
| IL247469B (en) | Methods for refining conjugates based on alpha il-15/il-15r, preparations containing products produced in this way and their uses | |
| SI2920149T1 (sl) | Spojine 3-aminocikloalkila kot zaviralci receptorja ROR-gama-t in uporaba teh spojin | |
| IL238959A0 (en) | Glutamase inhibitors, preparations containing them and their uses | |
| SG11201406868XA (en) | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | |
| PT2431442T (pt) | Composição à base de 1,3,3,3-tetrafluoropropeno | |
| ZA201403948B (en) | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof | |
| BR112013003536A2 (pt) | composição, e utilização de uma composição. | |
| IL223865A0 (en) | Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof | |
| EP3082823A4 (en) | Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use | |
| IL233529A0 (en) | 1, 5-naphthyridine derivatives and malac inhibitors containing them | |
| SG10201800741QA (en) | BENZO-[d][1,2,3]TRIAZINE COMPOUNDS AND USE AS p70S6K INHIBITORS | |
| ZA201307216B (en) | Novel oxazolidinone derivative and pharmaceutical composition including the same | |
| IL237331A0 (en) | 3,4-converted oxazolidinone derivatives and their use as calcium octave potassium channel inhibitors | |
| SG11201601921RA (en) | Azeotrope-like compositions of fo-e-1,3,4,4,4-pentafluoro-3-trifluoromethyl-1-butene and e-1-chloro-3,3,3-trifluoropropene and uses thereof | |
| TWI560186B (en) | Novel compound, phamraceutical composition or combination product comprising the same, and use thereof | |
| GB201409466D0 (en) | Urea compounds and their use as enzyme inhibitors | |
| UA70698U (ru) | Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства | |
| GB201313903D0 (en) | Urea compounds and their use as enzyme inhibitors | |
| GB201313786D0 (en) | Urea compounds and their use as enzyme inhibitors |